Document Detail

Asymmetric dimethylarginine (ADMA): a novel risk marker in cardiovascular medicine and beyond.
MedLine Citation:
PMID:  16581698     Owner:  NLM     Status:  MEDLINE    
There is abundant evidence that the endothelium plays a crucial role in the maintenance of vascular tone and structure. One of the major endothelium-derived vasoactive mediators is nitric oxide (NO), an endogenous messenger molecule formed in healthy vascular endothelium from the amino acid precursor L-arginine. Endothelial dysfunction is caused by various cardiovascular risk factors, metabolic diseases, and systemic or local inflammation. One mechanism that explains the occurrence of endothelial dysfunction is the presence of elevated blood levels of asymmetric dimethylarginine (ADMA)--an L-arginine analogue that inhibits NO formation and thereby can impair vascular function. Supplementation with L-arginine has been shown to restore vascular function and to improve the clinical symptoms of various diseases associated with vascular dysfunction.
Rainer H Böger
Related Documents :
19074078 - Mechanisms of vasculopathy in sickle cell disease and thalassemia.
10423088 - Endothelial dysfunction in hypertension.
22015658 - Disruption of endothelial peroxisome proliferator-activated receptor γ accelerates die...
16927678 - Impact of hemorheological and endothelial factors on microcirculation.
16790998 - The leukocyte-endothelial cell interactions are modulated by extracellular matrix prote...
23090948 - Hypoxia-reoxygenation-induced endothelial barrier failure: role of rhoa, rac1 and myosi...
Publication Detail:
Type:  Journal Article; Review    
Journal Detail:
Title:  Annals of medicine     Volume:  38     ISSN:  0785-3890     ISO Abbreviation:  Ann. Med.     Publication Date:  2006  
Date Detail:
Created Date:  2006-04-03     Completed Date:  2006-08-24     Revised Date:  2007-11-15    
Medline Journal Info:
Nlm Unique ID:  8906388     Medline TA:  Ann Med     Country:  Sweden    
Other Details:
Languages:  eng     Pagination:  126-36     Citation Subset:  IM    
Clinical Pharmacology Unit, Institute of Experimental and Clinical Pharmacology, University Hospital Hamburg-Eppendorf, Hamburg, Germany.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Arginine / analogs & derivatives*,  blood,  metabolism,  urine
Arteriosclerosis / blood,  diagnosis*
Biological Markers / blood
Cardiovascular Diseases / blood,  diagnosis*,  metabolism
Clinical Trials as Topic
Endothelium, Vascular / metabolism
Hyperthyroidism / blood
Insulin Resistance
Liver Failure / blood
Metabolic Syndrome X / blood
Nitric Oxide / metabolism
Nitric Oxide Synthase / antagonists & inhibitors*
Pre-Eclampsia / blood
Risk Factors
Reg. No./Substance:
0/Biological Markers; 10102-43-9/Nitric Oxide; 30344-00-4/N,N'-dimethylarginine; 74-79-3/Arginine; EC Oxide Synthase

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Treatment of airway mucus hypersecretion.
Next Document:  Mid-term outcome after carotid artery stenting depends on presence of coronary artery disease.